meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic/advanced mGC or mGEJC
mGC or mGEJC - 1st line (L1)
mGC or mGEJC - L1 - all population
mGC or mGEJC - L1 - HER2 neg/PDL1 positive
2
mGC or mGEJC - L1 - HER2 negative
1
mGC or mGEJC - L1 - HER2 positive
mGC or mGEJC - L1 - PDL1 positive
4
mGC or mGEJC - 2nd Line (L2)
mGC or mGEJC - L2 - all population
4
mGC or mGEJC - L2 - PDL1 positive
1
mGC or mGEJC - maintenance (M)
mGC or mGEJC - M - HER2 negative
1
mGC or mGEJC - M - HER2 neg/PDL1 positive
1
gene alteration defined cancer
gene alteration target therapy
KRAS gene alteration targeted therapy
sotorasib
NTRK gene alteration targeted therapy
larotrectinib
RET gene alteration targeted therapy
pralsetinib
selpercatinib
versus all
vs non active control
vs no control (uncontrolled study)
All patients
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
button
bars
forest
bayes
pooled
summary
circles
DOR
objective responses (ORR)
DOR
KRAS gene alteration defined cancer
KRAS gene alteration defined cancer
NTRK gene alteration
NTRK gene alteration
RET gene alteration defined cancer
RET gene alteration defined cancer
×
delta: difference in rate or median (if available)
×
Extraction panel open
An extraction panel is open